Risk Prediction Model for Necrotizing Pneumonia in Children with Mycoplasma pneumoniae Pneumonia

References

• Kutty PK, Jain S, Taylor TH, et al. Mycoplasma pneumoniae among children hospitalized with community-acquired pneumonia. Clin Infect Dis. 2019;68(1):5–12. doi:10.1093/cid/ciy419
   PubMed Web of Science ®Google Scholar
• Esposito S, Argentiero A, Gramegna A, et al. Mycoplasma pneumoniae: a pathogen with unsolved therapeutic problems. Expert Opin Pharmacother. 2021;22(9):1193–1202. doi:10.1080/14656566.2021.1882420
   PubMed Web of Science ®Google Scholar
• Atkinson TP, Balish MF, Waites KB. Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections. FEMS Microbiol Rev. 2008;32(6):956–973. doi:10.1111/j.1574-6976.2008.00129.x
   PubMed Web of Science ®Google Scholar
• Tsai YF, Ku YH. Necrotizing pneumonia: a rare complication of pneumonia requiring special consideration. Curr Opin Pulm Med. 2012;18(3):246–252. doi:10.1097/MCP.0b013e3283521022
   PubMed Web of Science ®Google Scholar
• Krenke K, Sanocki M, Urbankowska E, et al. Necrotizing pneumonia and its complications in children. Adv Exp Med Biol. 2015;857:9–17. doi:10.1007/5584_2014_99
   PubMed Web of Science ®Google Scholar
• Sawicki GS, Lu FL, Valim C, et al. Necrotising pneumonia is an increasingly detected complication of pneumonia in children. Eur Respir J. 2008;31(6):1285–1291. doi:10.1183/09031936.00099807
   PubMed Web of Science ®Google Scholar
• Hacimustafaoglu M, Celebi S, Sarimehmet H, et al. Necrotizing pneumonia in children. Acta Paediatr. 2004;93(9):1172–1177. doi:10.1080/08035250410026699
   PubMed Web of Science ®Google Scholar
• Zhou Y, Hu M, Ye B, et al. Early prediction of necrotizing pneumonia from mycoplasma pneumoniae pneumonia with large pulmonary lesions in children. Sci Rep. 2020;10(1):19061. doi:10.1038/s41598-020-76083-5
   PubMed Web of Science ®Google Scholar
• Zheng B, Zhao J, Cao L. The clinical characteristics and risk factors for necrotizing pneumonia caused by Mycoplasma pneumoniae in children. BMC Infect Dis. 2020;20(1):391. doi:10.1186/s12879-020-05110-7
   PubMed Web of Science ®Google Scholar
• Yang M, Meng F, Wang K, et al. Interleukin 17A as a good predictor of the severity of Mycoplasma pneumoniae pneumonia in children. Sci Rep. 2017;7(1):12934. doi:10.1038/s41598-017-13292-5
   PubMed Web of Science ®Google Scholar
• Chen Y, Li L, Wang C, et al. Necrotizing pneumonia in children: early recognition and management. J Clin Med. 2023;12(6):2256. doi:10.3390/jcm12062256
   PubMed Web of Science ®Google Scholar
• Cheng Q, Zhang H, Shang Y, et al. Clinical features and risk factors analysis of bronchitis obliterans due to refractory Mycoplasma pneumoniae pneumonia in children: a nomogram prediction model. BMC Infect Dis. 2021;21(1):1085. doi:10.1186/s12879-021-06783-4
   PubMed Web of Science ®Google Scholar
• Luo Y, Wang Y. Development of a nomogram for predicting massive necrotizing pneumonia in children. Infect Drug Resist. 2023;16:1829–1838. doi:10.2147/idr.S408198
   PubMed Web of Science ®Google Scholar
• Lee SC, Youn YS, Rhim JW, et al. Early serologic diagnosis of mycoplasma pneumoniae pneumonia: an observational study on changes in titers of specific-igm antibodies and cold agglutinins. Medicine. 2016;95(19):e3605. doi:10.1097/md.0000000000003605
   PubMed Web of Science ®Google Scholar
• Yang B, Zhang W, Gu W, et al. Differences of clinical features and prognosis between Mycoplasma pneumoniae necrotizing pneumonia and non-Mycoplasma pneumoniae necrotizing pneumonia in children. BMC Infect Dis. 2021;21(1):797. doi:10.1186/s12879-021-06469-x
   PubMed Web of Science ®Google Scholar
• Gong H, Sun B, Chen Y, et al. The risk factors of children acquiring refractory mycoplasma pneumoniae pneumonia: a meta-analysis. Medicine. 2021;100(11):e24894. doi:10.1097/md.0000000000024894
   PubMed Web of Science ®Google Scholar
• Huang L, Huang X, Jiang W, et al. Independent predictors for longer radiographic resolution in patients with refractory Mycoplasma pneumoniae pneumonia: a prospective cohort study. BMJ Open. 2018;8(12):e023719. doi:10.1136/bmjopen-2018-023719
   PubMed Web of Science ®Google Scholar
• Huang X, Li D, Liu F, et al. Clinical significance of D-dimer levels in refractory Mycoplasma pneumoniae pneumonia. BMC Infect Dis. 2021;21(1):14. doi:10.1186/s12879-020-05700-5
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhou Y, Li S, et al. The clinical characteristics and predictors of refractory mycoplasma pneumoniae pneumonia in children. PLoS One. 2016;11(5):e0156465. doi:10.1371/journal.pone.0156465
   PubMed Web of Science ®Google Scholar
• Panteghini M. Lactate dehydrogenase: an old enzyme reborn as a COVID-19 marker (and not only). Clin Chem Lab Med. 2020;58(12):1979–1981. doi:10.1515/cclm-2020-1062
   PubMed Web of Science ®Google Scholar
• Xie Q, Zhang X, Cui W, et al. Construction of a nomogram for identifying refractory mycoplasma pneumoniae pneumonia among macrolide-unresponsive mycoplasma pneumoniae pneumonia in children. J Inflamm Res. 2022;15:6495–6504. doi:10.2147/jir.S387809
   PubMed Web of Science ®Google Scholar
• Lv YT, Sun XJ, Chen Y, et al. Epidemic characteristics of Mycoplasma pneumoniae infection: a retrospective analysis of a single center in Suzhou from 2014 to 2020. Ann Transl Med. 2022;10(20):1123. doi:10.21037/atm-22-4304
   PubMed Web of Science ®Google Scholar
• Huang W, Xu X, Zhao W, et al. Refractory mycoplasma pneumonia in children: a systematic review and meta-analysis of laboratory features and predictors. J Immunol Res. 2022;2022:9227838. doi:10.1155/2022/9227838
   PubMed Web of Science ®Google Scholar
• Qiu J, Ge J, Cao L. D-dimer: the risk factor of children’s severe mycoplasma pneumoniae pneumonia. Front Pediatr. 2022;10:828437. doi:10.3389/fped.2022.828437
   PubMed Web of Science ®Google Scholar